Gene therapy in mouse models of Huntington disease

Neuroscientist

Volumn 17, Issue 2, 2011, Pages 153-162

  Southwell, Amber L ^a   Patterson, Paul H ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

autophagy; intrabody; neurotrophin; RNAi; silencing; viral vector

Indexed keywords

BINDING PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CHOLESTEROL; CILIARY NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HAPP 1 INTRABODY; HEAT SHOCK COGNATE PROTEIN 70; HUNTINGTIN; NERVE GROWTH FACTOR; NEUROTROPHIC FACTOR; NEUTURIN; NOGGIN; PHOSPHOPROTEIN DARPP 32; POLYQ BINDING PEPTIDE 1; PROTEIN ANTIBODY; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; ASTROCYTE; CALCIUM SIGNALING; CELL ACTIVATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL LOSS; CELL SURVIVAL; CELL TRANSPLANTATION; CORPUS STRIATUM; EXCITOTOXICITY; GENE MUTATION; GENE SILENCING; GENE TARGETING; GENE THERAPY; GENETIC ENGINEERING; HUNTINGTON CHOREA; MESENCHYMAL STEM CELL; MITOCHONDRION; NERVE CELL; NEURAL STEM CELL; NEUROPROTECTION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CALCIUM; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; GENE THERAPY; GREEN FLUORESCENT PROTEINS; HUMANS; HUNTINGTON DISEASE; MENTAL DISORDERS; MICE; MOVEMENT DISORDERS; MUTATION; NERVE GROWTH FACTORS; NERVE TISSUE PROTEINS; NEURAL STEM CELLS; NUCLEAR PROTEINS; RNA, SMALL INTERFERING;

EID: 79953897022     PISSN: 10738584     EISSN: 10894098     Source Type: Journal    
DOI: 10.1177/1073858410386236     Document Type: Article

References (83)

1. Alberch J., Pérez-Navarro E., Canals JM 2002. Neuroprotection by neurotrophins and GDNF family members in the excitotoxic model of Huntington's disease. Brain Res Bull 57 (6). 817-22. (Pubitemid 34522157)
2. Bauer PO, Goswami A., Wong HK, Okuno M., Kurosawa M., Yamada M., and others. 2010. Harnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein. Nat Biotech 28 (3). 256-63.
3. Bemelmans A-P., Horellou P., Pradier L., Brunet I., Colin P., Mallet J. 1999. Brain-derived neurotrophic factor-mediated protection of striatal neurons in an excitotoxic rat model of Huntington's disease, as demonstrated by adenoviral gene transfer. Hum Gene Ther 10 (18). 2987-97.
4. Biglan KM, Ross CA, Langbehn DR, Aylward EH, Stout JC, Queller S., and others. 2009. Motor abnormalities in pre-manifest persons with Huntington's disease: the PREDICT-HD study. Movement Disord 24 (12). 1763-72.
5. Bjorkqvist M., Wild EJ, Thiele J., Silvestroni A., Andre R., Lahiri N., and others. 2008. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J Exp Med 205 (8). 1869-77.
6. Boudreau R., McBride J., Martins I., Shen S., Xing Y., Carter B., and others. 2009. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington. Mol Ther 17 (6). 1053-63.
7. Cho S. -R, Benraiss A., Chmielnicki E., Samdani A., Economides A., Goldman SA 2007. Induction of neostriatal neurogenesis slows disease progression in a transgenic murine model of Huntington disease. J Clin Invest 117 (10). 2889-902. (Pubitemid 47529619)
8. Christine CW, Starr PA, Larson PS, Eberling JL, Jagust WJ, Hawkins RA, and others. 2009. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 73 (20). 1662-9.
9. Ciron C., Cressant A., Roux F., Raoul S., Cherel Y., Hantraye P., and others. 2009. AAV1-, AAV2- and AAV5-mediated human alpha-Iduronidase gene transfer in the brain of non-human primate: vector diffusion and bio distribution. Hum Gene Ther 20 (4). 350-60.
10. Cui L., Jeong H., Borovecki F., Parkhurst CN, Tanese N., Krainc D. 2006. Transcriptional repression of PGC-1α by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 127 (1). 59-69. (Pubitemid 44466642)
11. Dai Y., Dudek NL, Li Q., Fowler SC, Muma NA 2009. Striatal expression of a calmodulin fragment improved motor function, weight loss, and neuropathology in the R6/2 mouse model of Huntington's disease. J Neurosci 29 (37). 11550-9.
12. Damiano M., Galvan L., Déglon N., Brouillet E. 2010. Mitochondria in Huntington's disease. Biochim Biophys Acta (1). 52-61.
13. De Almeida LP, Zala D., Aebischer P., Déglon N. 2001. Neuroprotective effect of a CNTF-expressing lentiviral vector in the quinolinic acid rat model of Huntington's disease. Neurobiol Dis 8 (3). 433-46. (Pubitemid 32566134)
14. De Marchi N., Daniele F., Ragone MA 2001. Fluoxetine in the treatment of Huntington's disease. Psychopharmacology 153 (2). 264-6. (Pubitemid 32127897)
15. Denovan-Wright EM, Attis M., Rodriguez-Lebron E., Mandel RJ 2008. Sustained striatal ciliary neurotrophic factor expression negatively affects behavior and gene expression in normal and R6/1 mice. J Neurosci Res 86 (8). 1748-57. (Pubitemid 351859425)
16. Dey ND, Bombard MC, Roland BP, Davidson S., Lu M., Rossignol J., and others. 2010. Genetically engineered mesenchymal stem cells reduce behavioral deficits in the YAC 128 mouse model of Huntington's disease. Behav Brain Res 214 (2). 193-200.
17. DiFiglia M., Sena-Esteves M., Chase K., Sapp E., Pfister E., Sass M., and others. 2007. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. PNAS 104 (43). 17204-9. (Pubitemid 350211015)
18. Dragatsis I., Levine MS, Zeitlin S. 2000. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat Genet 26 (3). 300-6.
19. Drouet V., Perrin V., Hassig R., Dufour N., Auregan G., Alves S., and others. 2009. Sustained effects of nonallele-specific Huntingtin silencing. Ann Neurol 65 (3). 276-85.
20. Duff K., Paulsen JS, Beglinger LJ, Langbehn DR, Stout JC 2007. Psychiatric symptoms in Huntington's disease before diagnosis: the Predict-HD Study. BiolPsychiat 62 (12). 1341-6. (Pubitemid 350180721)
21. Ebert AD, Barber AE, Heins BM, Svendsen CN 2010. Ex vivo delivery of GDNF maintains motor function and prevents neuronal loss in a transgenic mouse model of Huntington's disease. Exp Neurol 224 (1). 155-62.
22. Emerich DF, Lindner MD, Winn SR, Chen E. -Y, Frydel BR, Kordower JH 1996. Implants of encapsulated human CNTFproducing fibroblasts prevent behavioral deficits and striatal degeneration in a rodent model of Huntington's disease. J Neurosci 16 (16). 5168-81. (Pubitemid 26269675)
23. Fiandaca MS, Varenika V., Eberling J., McKnight T., Bringas J., Pivirotto P, and others. 2009. Real-time MR imaging of adeno-associated viral vector delivery to the primate brain. NeuroImage 47 (Suppl 2). T27 - T35.
24. Franich NR, Fitzsimons HL, Fong DM, Klugmann M., During MJ, Young D. 2008. AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease. Mol Ther 16 (5). 947-56. (Pubitemid 351587106)
25. Giralt A., Friedman HC, Caneda-Ferron B., Urban N., Moreno E., Rubio N., and others. 2010. BDNF regulation under GFAP promoter provides engineered astrocytes as a new approach for long-term protection in Huntington's disease. Gene Ther 17: 1294-308.
26. Haque N., Isacson O. 2000. Neurotrophic factors NGF and FGF-2 alter levels of huntingtin (IT15) in striatal neuronal cell cultures. Cell Transplant 9 (5). 623-7. (Pubitemid 32002569)
27. Harper SQ 2009. Progress and challenges in RNA interference therapy for Huntington disease. Arch Neurol 66 (8). 933-8.
28. Harper SQ, Staber PD, He X., Eliason SL, Martins IH, Mao Q., and others. 2005. From the cover: RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. PNAS 102 (16). 5820-5. (Pubitemid 40559643)
29. Hu J., Matsui M., Corey DR 2009. Allele-selective inhibition of mutant huntingtin by peptide nucleic acid-peptide conjugates, locked nucleic acid, and small interfering RNA. Ann N Y Acad Sci 1175: 24-31.
30. Huang B., Schiefer J., Sass C., Landwehrmeyer GB, Kosinski CM, Kochanek S. 2007. High-capacity adenoviral vector-mediated reduction of huntingtin aggregate load in vitro and in vivo. Hum Gene Ther 18 (4). 303-311. (Pubitemid 46709342)
31. Huntington Study Group. 2006. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 66 (3). 366-72.
32. Huntington's Disease Collaborative Research Group. 1993. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72 (6). 971-83.
33. Imarisio S., Carmichael J., Korolchuk V., Chen C-W., Saiki S., Rose C., and others. 2008. Huntington's disease: from pathology and genetics to potential therapies. Biochem J 412 (2). 191-209. (Pubitemid 351758226)
34. Ip NY, Yancopoulos GD 1996. The neurotrophins and CNTF: two families of collaborative neurotrophic factors. Ann Rev Neurosci 19 (1). 491-515. (Pubitemid 26080837)
35. Jacobsen JC, Bawden CS, Rudiger SR, McLaughlan CJ, Reid SJ, Waldvogel HJ, and others. 2010. An ovine transgenic Huntington's disease model. Hum Mol Genet 19 (10). 1873-82.
36. Kaplitt MG, Feigin A., Tang C., Fitzsimons HL, Mattis P., Lawlor PA, and others. 2007. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369 (9579). 2097-105. (Pubitemid 46935946)
37. Kells AP, Fong DM, Dragunow M., During MJ, Young D., Connor B. 2004. AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease. Mol Ther 9 (5). 682-8. (Pubitemid 38660421)
38. Lecerf JM, Shirley TL, Zhu Q., Kazantsev A., Amersdorfer P., Housman DE and others. 2001. Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease. PNAS 98 (8). 4764-9. (Pubitemid 32295050)
39. Lombardi MS, Jaspers L., Spronkmans C., Gellera C., Taroni F., Di Maria E. and others. 2009. A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference. Exp Neurol 217 (2). 312-9.
40. Machida Y., Okada T., Kurosawa M., Oyama F., Ozawa K., Nukina N. 2006. rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse. Biochem Biophys Res Comm 343 (1). 190-7.
41. Mandel RJ 2010. CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease. Curr Op Mol Ther 12 (2). 240-7.
42. Marks WJJ, Ostrem JL, Verhagen L., Starr PA, Larson PS, Bakay RAE, and others. 2008. Safety and tolerability of intra-putaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol 7 (5). 400-8.
43. Martinez-Serrano A., Bjorklund A. 1996. Protection of the neostriatum against excitotoxic damage by neurotrophin-producing, genetically modified neural stem cells. J Neurosci 16 (15). 4604-16. (Pubitemid 26251057)
44. McBride JL, Boudreau RL, Harper SQ, Staber PD, Monteys AM, Martins IS, and others. 2008. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. PNAS 105 (15). 5868-73. (Pubitemid 351758464)
45. McBride JL, Ramaswamy S., Gasmi M., Bartus RT, Herzog CD, Brandon EP, and others. 2006. Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease. PNAS 103 (24). 9345-50. (Pubitemid 43902579)
46. Murphy RC, Messer A. 2004. A single-chain Fv intrabody provides functional protection against the effects of mutant protein in an organotypic slice culture model of Huntington's disease. Mol Brain Res 121 (1-2). 141-5. (Pubitemid 38224179)
47. Palfi S., Brouillet E., Jarraya B., Bloch J., Jan C., Shin M., and others. 2007. Expression of mutated huntingtin fragment in the putamen is sufficient to produce abnormal movement in non-human primates. Mol Ther 15 (8). 1444-51. (Pubitemid 47099301)
48. Panov AV, Gutekunst C-A., Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, and others. 2002. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci 5 (8). 731-6. (Pubitemid 34827590)
49. Passani LA, Bedford MT, Faber PW, McGinnis KM, Sharp AH, Gusella JF, and others. 2000. Huntingtin's WW domain partners in Huntington's disease post-mortem brain fulfill genetic criteria for direct involvement in Huntington's disease pathogenesis. Hum Mol Genet 9 (14). 2175-82.
50. Pérez-Navarro E., Åkerud P., Marco S., Canals JM, Tolosa E., Arenas E., and others. 2000. Neurturin protects striatal projection neurons but not interneurons in a rat model of Huntington's disease. Neuroscience 98 (1). 89-96. (Pubitemid 30349147)
51. Pérez-Navarro E., Arenas E., Marco S., Alberch J. 1999. Intrastriatal grafting of a GDNF-producing cell line protects striatonigral neurons from quinolinic acid excitotoxicity in vivo. Eur J Neurosci 11 (1). 241-9. (Pubitemid 29012328)
52. Pérez-Navarro E., Arenas E., Reiriz J., Calvo N., Alberch J. 1996. Glial cell line-derived neurotrophic factor protects striatal calbindin-immunoreactive neurons from excitotoxic damage. Neuroscience 75 (2). 345-52. (Pubitemid 26361327)
53. Pfister EL, Kennington L., Straubhaar J., Wagh S., Liu W., DiFiglia M. and others. 2009. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr Biol 19 (9). 774-8.
54. Pineda JR, Rubio N., Akerud P., Urban N., Badimon L., Arenas E., and others. 2006. Neuroprotection by GDNF-secreting stem cells in a Huntington's disease model: optical neuroimage tracking of brain-grafted cells. Gene Ther 14 (2). 118-28.
55. Popovic N., Maingay M., Kirik D., Brundin P. 2005. Lentiviral gene delivery of GDNF into the striatum of R6/2 Huntington mice fails to attenuate behavioral and neuropathological changes. Exp Neurol 193 (1). 65-74. (Pubitemid 40463268)
56. Qin Z-H., Wang Y., Sapp E., Cuiffo B., Wanker E., Hayden MR, and others. 2004. Huntingtin bodies sequester vesicle-associated proteins by a polyproline-dependent interaction. J Neurosci 24 (1). 269-81. (Pubitemid 38181691)
57. Ramaswamy S., McBride J., Han I., Berry-Kravis E., Zhou LH, Herzog CD, and others. 2008. Intrastriatal CERE-120 (AAV-neurturin) protects striatal and cortical neurons and delays motor deficits in a transgenic mouse model of Huntington. Neurobiol Dis 34 (1). 40-5.
58. Ramaswamy S., McBride JL, Herzog CD, Brandon E., Gasmi M., Bartus RT, and others. 2007. Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease. Neurobiol Dis 26 (2). 375-84. (Pubitemid 46561340)
59. Ramaswamy SS, Shannon Kmkm, Kordower Jhjh. 2007. Huntington's disease: pathological mechanisms and therapeutic strategies. Cell Transplant 16 (3). 301-12.
60. Ravikumar B., Vacher C., Berger Z., Davies JE, Luo S., Oroz LG, and others. 2004. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 36 (6). 585-95. (Pubitemid 38715985)
61. Régulier E., Pereira de Almeida L., Sommer B., Aebischer P., Déglon N. 2002. Dose-dependent neuroprotective effect of ciliary neurotrophic factor delivered via tetracycline-regulated lentiviral vectors in the quinolinic acid rat model of Huntington's disease. Hum Gene Ther 13 (16). 1981-90. (Pubitemid 35341039)
62. Rodriguez-Lebron E., Denovan-Wright EM, Nash K., Lewin AS, Mandel RJ 2005. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Mol Ther 12 (4). 618-33. (Pubitemid 41350143)
63. Rosas D., Salat D., Lee S., Zaleta A., Hevelone N., Hersch SM 2008. Complexity and heterogeneity: what drives the ever-changing brain in Huntington's disease ? Ann NY Acad Sci 1147: 196-205.
64. Rose C., Menzies FM, Renna M., Acevedo-Arozena A., Corrochano S., Sadiq O., and others. 2010. Rilmenidine attenuates toxicity of polyglutamine expansions in a mouse model of Huntington's disease. Hum Mol Genet 19 (11). 2144-53.
65. Sarkar S., Krishna G., Imarisio S., Saiki S., O'Kane CJ, Rubinsztein DC 2008. A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin. Hum Mol Genet 17 (2). 170-178.
66. Sarkar S., Rubinsztein DC 2008. Huntington's disease: degradation of mutant huntingtin by autophagy. FEBS J 275 (17). 4263-70.
67. Snyder-Keller A., Butler D., Messer A. 2010. Engineered antibody fragments can reduce Huntington's disease phenotypes in vivo and in situ. Program no 859.21, San Diego, CA.: Society for Neuroscience, Online.
68. Snyder-Keller A., McLear JA, Hathorn T., Messer A. 2010. Early or Late-Stage Anti-N-Terminal Huntingtin Intrabody Gene Therapy Reduces Pathological Features in B6.HDR6/1 Mice. J Neuropath Exp Neurol 69 (10). 1078-85.
69. Southwell AL, Bugg CW, Kaltenbach LS, Dunn DE, Butland SL, Weiss A., and others. 2010. Perturbation with intrabodies reveals that calpain cleavage is required for degradation of huntingtin exon 1. PLoS ONE 6 (1). e16676.
70. Southwell AL, Khoshnan A., Dunn DE, Bugg CW, Lo DC, Patterson PH 2008. Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity. J Neurosci 28 (36). 9013-20.
71. Southwell AL, Ko J., Patterson PH 2009. Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease. J Neurosci 29 (43). 13589-602.
72. Steffan JS, Kazantsev A., Spasic-Boskovic O., Greenwald M., Zhu Y-Z., Gohler H., and others. 2000. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. PNAS 97 (12). 6763-8. (Pubitemid 30412788)
73. Taupin P. and Gage FH 2002. Adult neurogenesis and neural stem cells of the central nervous system in mammals. J Neurosci Res 69 (6). 745-9. (Pubitemid 34984691)
74. Varenika V., Kells AP, Valles F., Hadaczek P., Forsayeth J., Bankiewicz KS, and others. 2009. Controlled dissemination of AAV vectors in the primate brain. Prog Brain Res 175: 163-72.
75. Walker FO 2007. Huntington's disease. Lancet 369 (9557). 218-28. (Pubitemid 46107685)
76. Wang C-E., Zhou H., McGuire JR, Cerullo V., Lee B., Li S-H., and others. 2008. Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin. J Cell Biol 181 (5). 803-16. (Pubitemid 351786985)
77. Wang Y. -L, Liu W., Wada E., Murata M., Wada K., Kanazawa I. 2005. Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA. Neurosci Res 53 (3). 241-9. (Pubitemid 41463777)
78. White JK, Auerbach W., Duyao MP, Vonsattel JP, Gusella JF, Joyner AL, and others. 1997. Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion. Nat Genet 17 (4). 404-10. (Pubitemid 27518388)
79. Yang D., Wang C-E., Zhao B., Li W., Ouyang Z., Liu Z., and others. 2010. Expression of Huntington's disease protein results in apoptotic neurons in the brains of cloned transgenic pigs. Hum Mol Genet 19 (20). 3983-94.
80. Yang S-H., Cheng P-H., Banta H., Piotrowska-Nitsche K., Yang J-J., Cheng ECH, and others. 2008. Towards a transgenic model of Huntington's disease in a non-human primate. Nature 453 (7197). 921-4. (Pubitemid 351832563)
81. Zala D., Bensadoun J-C., Pereira de Almeida L., Leavitt BR, Gutekunst C-A., Aebischer P., and others. 2004. Long-term lentiviral-mediated expression of ciliary neurotrophic factor in the striatum of Huntington's disease transgenic mice. Exp Neurol 185 (1). 26-35. (Pubitemid 38010276)
82. Zuccato C., Cattaneo E. 2007. Role of brain-derived neurotrophic factor in Huntington's disease. Prog Neurobiol 81 (5-6). 294-330. (Pubitemid 46528643)
83. Zuccato C., Valenza M., Cattaneo E. 2010. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev 90 (3). 905-81.